NA Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143404
- Pages: 225
-
Format:
Short Description
North America Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Market Definition:
Leber congenital amaurosis (LCA) is defined as a type of disorder of the eye which mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for the detection of light and colour.
Leber congenital amaurosis (LCA) is a rare inherited eye disease that appears at birth or in the first few months of life. It affects about 1 in 40,000 newborns. People with this disorder typically have severe visual impairment beginning in infancy. The visual impairment tends to be stable, although it may worsen very slowly over time.
Market Segmentation:
North America leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others.
On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy.
On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others.
Market Players
The key market players for North America leber congenital amaurosis market are listed below:
Invitae Corporation
Spark Therapeutics, Inc.
LKC TECHNOLOGIES, INC
CENTOGENE N.V.
Optos, Metrovision
Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics)
CD Genomics
ProQR Therapeutics
OCUGEN, INC.
MeiraGTx Limited
Coave Therapeutics
IVERIC bio, Inc.
Atsena Therapeutics
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Allergan (A Subsidiary of Abbvie Inc.)
AGTC
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
REGENXBIO Inc
TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET 43
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 DISEASE TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET END USER COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PIPELINE ANALYSIS FOR NORTH AMERICA LEBER CONGENTIAL AMAUROSIS MARKET 65
4.2 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 67
4.3 PESTEL ANALYSIS 70
4.4 PORTERS FIVE FORCES 71
5 EPIDEMIOLOGY 72
6 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 73
6.1 DRIVERS 75
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 75
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 78
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 84
6.2 RESTRAINTS 85
6.2.1 LACK OF QUALIFIED PROFESSIONALS 85
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 86
6.3 OPPORTUNITIES 87
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 87
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 87
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 88
6.4 CHALLENGES 89
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 89
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 89
7 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 90
7.1 OVERVIEW 91
7.2 INFANTILE TYPE 94
7.3 JUVENILE TYPE 94
7.4 OTHERS 95
8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 96
8.1 OVERVIEW 97
8.2 THERAPY 100
8.2.1 GENE THERAPY 101
8.2.1.1 LUXTURNA 101
8.2.2 RETINAL PROSTHETIC 101
8.2.3 NEUROPROTECTIVE AGENTS 101
8.2.3.1 VITAMIN A PALMITATE 102
8.2.3.2 DOCOSAHEXAENOIC ACID 102
8.2.3.3 LUTEIN 102
8.2.3.4 OTHERS 102
8.2.4 OTHERS 102
8.3 DIAGNOSIS 103
8.3.1 CLINICAL DIAGNOSIS 104
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 104
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 105
8.3.1.1.2 DARK ADAPTOMETRY (DA) 105
8.3.1.2 RETINAL IMAGING 105
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 105
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 106
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 106
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 106
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 106
8.3.1.3 VISUAL FIELD TEST 106
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 106
8.3.1.3.2 MANUAL FIELD TEST 106
8.3.1.4 CLINICAL EYE EXAMINATION 107
8.3.1.4.1 SLIT LAMP 107
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 107
8.3.1.4.3 REFRACTION TEST 107
8.3.1.4.4 DILATION EXAM 107
8.3.1.5 OTHERS 107
8.3.2 GENETIC DIAGNOSIS 108
9 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 109
9.1 OVERVIEW 110
9.2 HOSPITALS 113
9.3 SPECIALITY CLINICS 114
9.4 AMBULATORY SURGICAL CENTERS 115
9.5 HOME HEALTHCARE 116
9.6 OTHERS 117
10 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 118
10.1 OVERVIEW 119
10.2 RETAIL SALES 122
10.2.1.1 HOSPITAL PHARMACIES 123
10.2.1.2 RETAIL PHARMACIES 123
10.2.1.3 OTHERS 123
10.3 DIRECT TENDER 123
11 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 124
11.1 NORTH AMERICA 125
11.1.1 U.S. 132
11.1.2 CANADA 136
11.1.3 MEXICO 140
12 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 144
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 144
13 SWOT ANALYSIS 145
14 COMPANY PROFILE 146
14.1 SPARK THERAPEUTICS, INC 146
14.1.1 COMPANY SNAPSHOT 146
14.1.2 COMPANY SHARE ANALYSIS 146
14.1.3 PRODUCT PORTFOLIO 147
14.1.4 RECENT DEVELOPMENT 147
14.1.4.1 EU AUTHORIZATION 147
14.2 OPTOS 148
14.2.1 COMPANY SNAPSHOT 148
14.2.2 COMPANY SHARE ANALYSIS 148
14.2.3 PRODUCT PORTFOLIO 149
14.2.4 RECENT DEVELOPMENT 149
14.2.4.1 PRODUCT APPROVAL 149
14.3 CD GENOMICS 150
14.3.1 COMPANY SNAPSHOT 150
14.3.2 COMPANY SHARE ANALYSIS 150
14.3.3 PRODUCT PORTFOLIO 151
14.3.4 RECENT DEVELOPMENT 151
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 152
14.4.1 COMPANY SNAPSHOT 152
14.4.2 REVENUE ANALYSIS 152
14.4.3 COMPANY SHARE ANALYSIS 153
14.4.4 PRODUCT PORTFOLIO 153
14.4.5 RECENT DEVELOPMENTS 153
14.4.5.1 COLLABORATION 153
14.5 LKC TECHNOLOGIES, INC 154
14.5.1 COMPANY SNAPSHOT 154
14.5.2 COMPANY SHARE ANALYSIS 154
14.5.3 PRODUCT PORTFOLIO 155
14.5.4 RECENT DEVELOPMENT 155
14.5.4.1 PRODUCT APPROVAL 155
14.5.5 PRODUCT APPROVAL 155
14.6 AGTC 156
14.6.1 COMPANY SNAPSHOT 156
14.6.2 REVENUE ANALYSIS 156
14.6.3 PRODUCT PORTFOLIO 157
14.6.4 RECENT DEVELOPMENTS 157
14.6.4.1 AGREEMENT 157
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 158
14.7.1 COMPANY SNAPSHOT 158
14.7.2 REVENUE ANALYSIS 158
14.7.3 PRODUCT PORTFOLIO 159
14.7.4 RECENT DEVELOPMENTS 159
14.8 ASTELLAS PHARMA INC. 160
14.8.1 COMPANY SNAPSHOT 160
14.8.2 REVENUE ANALYSIS 160
14.8.3 PRODUCT PORTFOLIO 161
14.8.4 RECENT DEVELOPMENT 161
14.9 ATSENA THERAPEUTICS 162
14.9.1 COMPANY SNAPSHOT 162
14.9.2 PRODUCT PORTFOLIO 162
14.9.3 RECENT DEVELOPMENT 162
14.10 CENTOGENE N.V. 163
14.10.1 COMPANY SNAPSHOT 163
14.10.2 REVENUE ANALYSIS 163
14.10.3 PRODUCT PORTFOLIO 164
14.10.4 RECENT DEVELOPMENT 164
14.10.4.1 PRODUCT LAUNCH 164
14.11 COAVE THERAPEUTICS 165
14.11.1 COMPANY SNAPSHOT 165
14.11.2 PRODUCT PORTFOLIO 165
14.11.3 RECENT DEVELOPMENT 165
14.12 EDITAS MEDICINE 166
14.12.1 COMPANY SNAPSHOT 166
14.12.2 REVENUE ANALYSIS 166
14.12.3 PRODUCT PORTFOLIO 167
14.12.4 RECENT DEVELOPMENTS 167
14.12.4.1 DATA & TRAIL DATA PRESENTATION 167
14.13 ELUMINEX BIOSCIENCES 168
14.13.1 COMPANY SNAPSHOT 168
14.13.2 PRODUCT PORTFOLIO 168
14.13.3 RECENT DEVELOPMENT 168
14.14 GYROSCOPE THERAPEUTICS LIMITED 169
14.14.1 COMPANY SNAPSHOT 169
14.14.2 PRODUCT PORTFOLIO 169
14.14.3 RECENT DEVELOPMENTS 169
14.15 INVITAE CORPORATION 171
14.15.1 COMPANY SNAPSHOT 171
14.15.2 REVENUE ANALYSIS 171
14.15.3 PRODUCT PORTFOLIO 172
14.15.4 RECENT DEVELOPMENTS 172
14.15.4.1 NEW FACILITY 172
14.15.4.2 EXPANSION 172
14.16 IVERIC BIO. 173
14.16.1 COMPANY SNAPSHOT 173
14.16.2 PRODUCT PORTFOLIO 173
14.16.3 RECENT DEVELOPMENT 173
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 174
14.17.1 COMPANY SNAPSHOT 174
14.17.2 REVENUE ANALYSIS 174
14.17.3 PRODUCT PORTFOLIO 175
14.17.4 RECENT DEVELOPMENTS 175
14.18 MEIRAGTX LIMITED 176
14.18.1 COMPANY SNAPSHOT 176
14.18.2 PRODUCT PORTFOLIO 176
14.18.3 RECENT DEVELOPMENT 176
14.19 METROVISION 178
14.19.1 COMPANY SNAPSHOT 178
14.19.2 PRODUCT PORTFOLIO 178
14.19.3 RECENT DEVELOPMENT 178
14.19.3.1 FDA CLEARANCE APPROVAL 178
14.20 OCUGEN INC. 179
14.20.1 COMPANY SNAPSHOT 179
14.20.2 PRODUCT PORTFOLIO 179
14.20.3 RECENT DEVELOPMENT 179
14.21 OKUVISION 180
14.21.1 COMPANY SNAPSHOT 180
14.21.2 PRODUCT PORTFOLIO 180
14.21.3 RECENT DEVELOPMENTS 180
14.21.3.1 APPROVAL 180
14.22 PROQR THERAPEUTICS 181
14.22.1 COMPANY SNAPSHOT 181
14.22.2 PRODUCT PORTFOLIO 181
14.22.3 RECENT DEVELOPMENTS 181
14.23 REGENXBIO INC. 182
14.23.1 COMPANY SNAPSHOT 182
14.23.2 REVENUE ANALYSIS 182
14.23.3 PRODUCT PORTFOLIO 183
14.23.4 RECENT DEVELOPMENTS 183
14.24 SPARINGVISION 184
14.24.1 COMPANY SNAPSHOT 184
14.24.2 PRODUCT PORTFOLIO 184
14.24.3 RECENT DEVELOPMENTS 184
15 QUESTIONNAIRE 185
16 RELATED REPORTS 188
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
